SCHEMBL5880182

SCHEMBL5880182

Cc1cccc(/C=N/NC(=O)Cc2cccc(Cl)c2)c1OS(=O)(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
ANO1 Q5XXA6 3/20 0.43
LMNA P02545 3/20 0.43
FFAR2 O15552 2/20 0.42
CSNK1D P48730 1/20 0.41
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
MAPT P10636 1/20 0.40
SGK1 O00141 1/20 0.40
KDM4E B2RXH2 1/20 0.39
PKM P14618 1/20 0.39
ALOX15 P16050 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
POLB P06746 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5880186 1.00 MEN1 (0.47) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5880075 0.90 LMNA (0.45) MEN1KMT2ALMNAFFAR2CSNK1D
SCHEMBL5880072 0.90 LMNA (0.45) MEN1KMT2ALMNAFFAR2CSNK1D
SCHEMBL5880163 0.87 CYP1A2 (0.49) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5880161 0.87 CYP1A2 (0.49) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5879941 0.86 MEN1 (0.46) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5879945 0.86 MEN1 (0.46) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5879981 0.86 POLB (0.46) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5879984 0.86 POLB (0.46) MEN1KMT2AANO1LMNAFFAR2
SCHEMBL5879755 0.85 CSNK1D (0.43) MEN1KMT2AANO1LMNAFFAR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 MEN1 4884/4885KMT2A 1234/4885ANO1 3773/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.